<DOC>
	<DOCNO>NCT01281189</DOCNO>
	<brief_summary>The purpose study determine whether dexpramipexole ( 150 mg twice daily ) safe effective treatment Amyotrophic Lateral Sclerosis ( ALS ) .</brief_summary>
	<brief_title>Phase 3 Study Dexpramipexole ALS</brief_title>
	<detailed_description>Amyotrophic Lateral Sclerosis ( ALS ) rapidly progressive , degenerative disease motor neuron brain spinal cord lead muscle atrophy spasticity limb bulbar muscle result weakness loss ambulation , oropharyngeal dysfunction , weight loss , ultimately respiratory failure . The purpose study determine whether dexpramipexole ( 150 mg twice daily ) safe effective treatment ALS .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Aged 18 80 year old , inclusive , Day 1 . Diagnosis sporadic familial ALS . Onset first ALS symptom within 24 month prior Day 1 . World Federation Neurology El Escorial criterion meet possible , laboratorysupported probable , probable , definite ALS diagnosis . Upright slow vital capacity ( SVC ) 65 % screening . Patients take take Riluzole eligible study : patient never take Riluzole , eligible ; patient currently take Riluzole , must stable dose least 60 day ; patient discontinue Riluzole , must stop take least 30 day . Must able swallow tablet time study entry . Other medically significant illness . Clinically significant abnormal laboratory value . Pregnant woman woman breastfeed . Prior exposure dexpramipexole . Currently take pramipexole dopamine agonist . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>ALS</keyword>
	<keyword>Motor Neurone Disease</keyword>
</DOC>